Annual Report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2023 and Annual Treatment Report for 2018.

چکیده اصلی

AIM: To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2023 and the Annual Treatment Report for 2018 on the outcomes of patients who started treatment in 2018. METHODS: The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2023 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2018 was analyzed by using the Kaplan-Meier, log-rank, and Wilcoxon tests. RESULTS: Treatment was initiated in 2023 for 8061 patients with cervical cancer, 15 455 with endometrial cancer, 8844 with ovarian, tubal, and peritoneal cancer, 2316 with ovarian borderline tumors, and with the others (230 vulvar cancer, 157 vaginal cancer, 533 uterine sarcoma, 54 uterine adenosarcoma, 132 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5-year survival rates of the patients who initiated treatment in 2018 were as follows. For cervical cancer, the rates were 92.6%, 75.7%, 57.3%, and 25.9% for Stages I, II, III, and IV, respectively. For endometrial cancer, the rates were 94.3%, 88.3%, 75.2%, and 32.1% for Stages I, II, III, and IV, respectively. For ovarian cancer, the rates were 90.9%, 79.2%, 53.4%, and 41.1% for Stages I, II, III, and IV, respectively. CONCLUSION: The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.

متن کامل اصلی